Strides Pharma Science stated on Monday that it has entered into a sub-licensing deal with the Medicines Patent Pool (MPP) to offer a generic version of Pfizer’s Covid-19 oral medication in 95 low- and middle-income countries. Pfizer’s Covid-19 oral antiviral medication has been granted emergency use authorization by the US Food and Drug Administration (USFDA).
As part of Strides’ sub-licensing arrangement with MPP, the generic version of Pfizer’s oral medicine, Kovidax, will be marketed in markets. The device will be manufactured in the company’s Bengaluru location. Strides stated that it has previously secured supplies of active medicinal ingredients through a preferred partnership agreement.
Nirmatrelvir tablets are co-packaged and co-administered with Ritonavir tablets in this medicine. The medicine has been approved as a Covid-19 oral treatment for emergency use in high-risk adults and high-risk paediatric patients in the United States and many other countries.
When compared to a placebo, Pfizer’s Covid-19 oral therapy lowered the risk of hospitalisation or death by 89 percent within three days after symptom onset.
It is taken twice daily for five days as a combination of 300 mg Nirmatrelvir and 100 mg Ritonavir tablet.
